Lilly Zyprexa IM Agitation Use Should Be Limited To Patients Studied In Trials
Executive Summary
Lilly's antipsychotic Zyprexa intramuscular injection is safe and effective for the treatment of agitation in schizophrenia, bipolar I disorder and dementia, FDA's Psychopharmacological Drugs Advisory Committee concluded in a unanimous vote Feb. 14.
You may also be interested in...
Pfizer Adds Muscle To Geodon; IM Could Agitate Schizophrenia Market
Pfizer's intramuscular formulation of Geodon (ziprasidone) is indicated for "rapid control of agitation" in schizophrenic patients
Pfizer Adds Muscle To Geodon; IM Could Agitate Schizophrenia Market
Pfizer's intramuscular formulation of Geodon (ziprasidone) is indicated for "rapid control of agitation" in schizophrenic patients
Lilly Zyprexa IM "Approvable"; GMP Consultants Hired In Wake Of Inspections
Lilly believes Zyprexa IM is on track for a late summer launch following receipt of an "approvable" letter from FDA.